4.4 Article

Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment

Related references

Note: Only part of the references are listed.
Article Clinical Neurology

Six-Month Use of Droxidopa for Neurogenic Orthostatic Hypotension

Clement Francois et al.

MOVEMENT DISORDERS CLINICAL PRACTICE (2019)

Article Clinical Neurology

Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension

Italo Biaggioni et al.

BMC NEUROLOGY (2017)

Article Peripheral Vascular Disease

Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension

Stuart Isaacson et al.

JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2016)

Article Clinical Neurology

The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale

Horacio Kaufmann et al.

CLINICAL AUTONOMIC RESEARCH (2012)